Eckert & Ziegler Strahlen- und Medizintechnik AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eckert & Ziegler Strahlen- und Medizintechnik AG
The global market for prostate cancer diagnostics is expected to see double-digit growth, reaching $460.5m in 2023 and is driven by new technologies, in particular liquid biopsies and new genetic marker tests, according to a new report by Informa's Meddevicetracker.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-October 2013.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.
- Group Purchasing
- Home Infusion
- Managed Care, Insurance, Integrated Systems
- Outcomes Studies
- Services sold to health care facilities
- Specialized outpatient services
- Utilization Review, Claims Processing, Cost Contai
Managed Care, Insurance, Integrated Systems
- Specialized Provider Networks
- Specialty Pharmaceuticals
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- BEBIG Isotopentechnik und Umweltdiagnostik GmbH
- Eckert & Ziegler BEBIG GmbH
- Eckert & Ziegler BEBIG S.A.
- Gamma- Service- Produktbestrahlung GmBH
- Mick Radio-Nuclear Instruments